biostudies-literatureDondo TBBritish Heart FoundationMedical Research CouncilNational Institute for Health Research (NIHR)e011600https://www.ebi.ac.uk/biostudies/studies/S-EPMC4947744biostudies-literatureUnknown6(7)<h4>Objectives</h4>To investigate geographic variation in guideline-indicated treatments for non-ST-elevation myocardial infarction (NSTEMI) in the English National Health Service (NHS).<h4>Design</h4>Cohort study using registry data from the Myocardial Ischaemia National Audit Project.<h4>Setting</h4>All Clinical Commissioning Groups (CCGs) (n=211) in the English NHS.<h4>Participants</h4>357 228 patients with NSTEMI between 1 January 2003 and 30 June 2013.<h4>Main outcome measure</h4>Proportion of eligible NSTEMI who received all eligible guideline-indicated treatments (optimal care) according to the date of guideline publication.<h4>Results</h4>The proportion of NSTEMI who received optimal care was low (48 257/357 228; 13.5%) and varied between CCGs (median 12.8%, IQR 0.7-18.1%). The greatest geographic variation was for aldosterone antagonists (16.7%, 0.0-40.0%) and least for use of an ECG (96.7%, 92.5-98.7%). The highest rates of care were for acute aspirin (median 92.8%, IQR 88.6-97.1%), and aspirin (90.1%, 85.1-93.3%) and statins (86.4%, 82.3-91.2%) at hospital discharge. The lowest rates were for smoking cessation advice (median 11.6%, IQR 8.7-16.6%), dietary advice (32.4%, 23.9-41.7%) and the prescription of P2Y12 inhibitors (39.7%, 32.4-46.9%). After adjustment for case mix, nearly all (99.6%) of the variation was due to between-hospital differences (median 64.7%, IQR 57.4-70.0%; between-hospital variance: 1.92, 95% CI 1.51 to 2.44; interclass correlation 0.996, 95% CI 0.976 to 0.999).<h4>Conclusions</h4>Across the English NHS, the optimal use of guideline-indicated treatments for NSTEMI was low. Variation in the use of specific treatments for NSTEMI was mostly explained by between-hospital differences in care. Performance-based commissioning may increase the use of NSTEMI treatments and, therefore, reduce premature cardiovascular deaths.<h4>Trial registration number</h4>NCT02436187.BMJ openGeographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.PMC4947744RP-PG-0407-10314NIHR-CTF-2014-03-03PG/13/81/3047405/40/04NF-SI-0513-10130PG/13/81/3047MC_PC_13041G0902393MR/K006584/1Hall MHemingway HBloor KYan ATAlabas OATimmis ADOliver GDeanfield JEGale CPDondo TBBatin PDNorman PfalseGeographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.<h4>Objectives</h4>To investigate geographic variation in guideline-indicated treatments for non-ST-elevation myocardial infarction (NSTEMI) in the English National Health Service (NHS).<h4>Design</h4>Cohort study using registry data from the Myocardial Ischaemia National Audit Project.<h4>Setting</h4>All Clinical Commissioning Groups (CCGs) (n=211) in the English NHS.<h4>Participants</h4>357 228 patients with NSTEMI between 1 January 2003 and 30 June 2013.<h4>Main outcome measure</h4>Proportion of eligible NSTEMI who received all eligible guideline-indicated treatments (optimal care) according to the date of guideline publication.<h4>Results</h4>The proportion of NSTEMI who received optimal care was low (48 257/357 228; 13.5%) and varied between CCGs (median 12.8%, IQR 0.7-18.1%). The greatest geographic variation was for aldosterone antagonists (16.7%, 0.0-40.0%) and least for use of an ECG (96.7%, 92.5-98.7%). The highest rates of care were for acute aspirin (median 92.8%, IQR 88.6-97.1%), and aspirin (90.1%, 85.1-93.3%) and statins (86.4%, 82.3-91.2%) at hospital discharge. The lowest rates were for smoking cessation advice (median 11.6%, IQR 8.7-16.6%), dietary advice (32.4%, 23.9-41.7%) and the prescription of P2Y12 inhibitors (39.7%, 32.4-46.9%). After adjustment for case mix, nearly all (99.6%) of the variation was due to between-hospital differences (median 64.7%, IQR 57.4-70.0%; between-hospital variance: 1.92, 95% CI 1.51 to 2.44; interclass correlation 0.996, 95% CI 0.976 to 0.999).<h4>Conclusions</h4>Across the English NHS, the optimal use of guideline-indicated treatments for NSTEMI was low. Variation in the use of specific treatments for NSTEMI was mostly explained by between-hospital differences in care. Performance-based commissioning may increase the use of NSTEMI treatments and, therefore, reduce premature cardiovascular deaths.<h4>Trial registration number</h4>NCT02436187.2016-01-01T00:00:00Z2016 Jul2026-06-08T06:48:00.582Z2026-06-08T03:14:01.06ZS-EPMC49477442740664610.1136/bmjopen-2016-011600